𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of entacapone on plasma homocysteine levels in Parkinson’s disease patients

✍ Scribed by Martin Nevrly; Petr Kanovsky; Hana Vranova; Katerina Langova; Petr Hlustik

Publisher
Springer Milan
Year
2010
Tongue
English
Weight
196 KB
Volume
31
Category
Article
ISSN
1590-1874

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of levodopa and COMT inhibitors
Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients
✍ Paolo Lamberti; Stefano Zoccolella; Giovanni Iliceto; Elio Armenise; Angela Frad 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Abstract Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). T

Homocysteine levels after acute levodopa
Homocysteine levels after acute levodopa intake in patients with Parkinson's disease
✍ Thomas Müller; Wilfried Kuhn 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract Levodopa (L‐dopa) administered with a dopadecarboxylase inhibitor (DDI) increases homocysteine plasma levels. This may support the onset of atherosclerosis‐related disorders and neuropsychiatric complications in patients with Parkinson's disease (PD). This homocysteine elevation is cons

Entacapone improves absorption of a coad
Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease
✍ Thomas Müller; Dirk Woitalla; Oliver Goetze; Christoph Erdmann 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB

## Abstract Entacapone (EN) improves the efficacy of levodopa/dopadecarboxylase inhibitor (LD/DDI) formulations by inhibition of the enzyme catechol‐__O__‐methyltransferase (COMT). COMT inhibition also promotes the synthesis of basic LD metabolites, whereas DDI support the composition of acidic LD